Effect of a Medium Chain Triglyceride Supplemented Diet on Cognitive Function and Brain Activation in Type 1 Diabetes.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01315171|
Recruitment Status : Completed
First Posted : March 15, 2011
Last Update Posted : January 17, 2018
|Condition or disease||Intervention/treatment||Phase|
|Hypo-unawareness Type 1 Diabetes Mellitus||Dietary Supplement: Medium chain triglycerides||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of a Long-term Medium Chain Supplemented Diet on Cognitive Function and Brain Activation During Hypoglycemia in Type 1 Diabetes.|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||August 2015|
|Actual Study Completion Date :||October 2016|
Experimental: Medium chain supplemented diet
Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
Dietary Supplement: Medium chain triglycerides
4 tablespoons/day for 2 weeks
No Intervention: Standard group
Subjects will continue with a standard western diabetes diet.
- Cognitive function tests [ Time Frame: 100 minutes ]Cognitive function will be assessed during hypoglycemia. 3 tests will be carried looking at working memory with number and word recollection.
- Brain activity [ Time Frame: 100 minutes ]The fMRI will be used to assess brain activity during hypoglycemia in the presence of medium chain triglycerides.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315171
|United States, Connecticut|
|Yale University School of Medicine|
|New Haven, Connecticut, United States, 06511|
|Principal Investigator:||Robert Sherwin, MD||Yale University|